Medpace Holdings, Inc.

Medpace Holdings, Inc. is a clinical research organization that provides drug and medical device development services. The company supports the entire clinical development process from Phase I to Phase IV trials across various therapeutic areas. Its services include development plan design, project management, regulatory affairs, clinical monitoring, data management, biostatistical analysis, pharmacovigilance, and post-marketing clinical support. Medpace also offers specialized services such as bio-analytical laboratory work, clinical human pharmacology, imaging services, and electrocardiography reading for clinical trials. The company serves the pharmaceutical, biotechnology, and medical device industries, helping them bring new therapies to market efficiently.

Medpace Holdings, Inc. is listed on the Nasdaq Global Select Market (NasdaqGS) under the ticker symbol MEDP. The company's shares are traded in US dollars (USD), reflecting its primary listing in the United States. As a Nasdaq-listed company, Medpace is subject to the exchange's listing requirements and reporting standards, providing transparency for investors.

Medpace operates in the Healthcare sector, specifically within the Diagnostics & Research industry. This industry encompasses companies that provide analytical or diagnostic services, including clinical trial support and laboratory testing. Medpace's focus on clinical research services for drug and medical device development places it squarely in this category, as it helps clients design and execute studies to evaluate the safety and efficacy of new treatments.

Medpace is headquartered in Cincinnati, Ohio, United States. The company was founded in 1992 and has since expanded its operations globally. Medpace provides its clinical research services across North America, Europe, Asia, South America, Africa, and Australia. This broad geographic reach allows the company to support multinational clinical trials and serve clients worldwide, leveraging local expertise and regulatory knowledge in various regions.

Medpace generates revenue by offering a comprehensive suite of clinical development services to pharmaceutical, biotechnology, and medical device companies. The company earns fees for managing and executing clinical trials, from early-phase studies through post-marketing support. Services include project management, regulatory affairs, clinical monitoring, data management, and specialized laboratory services. Medpace typically contracts with clients on a project-by-project basis, with revenue recognized as services are performed. The company's expertise in therapeutic areas and global operational capabilities enable it to secure contracts for complex, large-scale trials.